1 Division of Cardiovascular and Thoracic Surgery, 2 Division of Vascular Surgery, Department of Surgery, Duke University Medical Center, Durham, North Carolina, USA.
Ann Cardiothorac Surg. 2014 May;3(3):264-74. doi: 10.3978/j.issn.2225-319X.2014.05.07.
Thoracic endovascular aortic repair (TEVAR) has become the preferred treatment for chronic type B aortic dissection (CTBAD) at our institution. However, it remains incapable of treating all patients with CTBAD. The present study aims to review our contemporary results with open and endovascular CTBAD repairs since the advent of thoracic endografting.
The records of all patients undergoing index repair of CTBAD (chronic DeBakey type IIIA, IIIB and repaired type I) at our institution between June 2005 and December 2013, were retrospectively reviewed.
A total of 107 patients underwent CTBAD repair, of whom 70% (n=75) underwent endovascular-based procedures [44 TEVAR, 27 hybrid arch and four hybrid thoracoabdominal aortic aneurysm (TAAA) repair] and 30% (n=32) underwent open procedures (nine open descending and 23 open TAAA). Connective tissue disease (CTD), prior aortic surgery and DeBakey dissection type were strongly associated with the choice of operation. The rates of stroke, paraplegia and operative mortality following endovascular-based repairs were 0%, 0% and 4% (n=3), respectively. Adverse neurologic events were higher following open repair, and rates of stroke, paraplegia, and operative mortality were 16% (n=5), 9% (n=3), and 6% (n=2), respectively. However, 1- and 5-year survival rates were similar for endovascular-based repairs (86% and 65%, respectively), and open repairs (88% and 79%, respectively). Over a median follow-up interval of 34 months, the rate of descending aortic reintervention was 24% (n=18) following endovascular-based repairs and 0% following open repairs (P=0.001). Forty-four percent (n=8) of descending aortic reinterventions were required to treat stent graft complications (five endoleak, two stent graft collapse and one stent graft-induced new entry tear) and the remainder were required to treat metachronous pathology (n=2) or progressive aneurysmal disease related to persistent distal fenestrations (n=8).
Endovascular repair of CTBAD was associated with excellent procedural and survival outcomes, but at the expense of further reinterventions. Open repair remains relevant for patients who are not candidates for endovascular repair and was associated with higher procedural morbidity but similar overall survival and fewer reinterventions.
在我院,胸主动脉腔内修复术(TEVAR)已成为慢性 B 型主动脉夹层(CTBAD)的首选治疗方法。然而,它仍然无法治疗所有 CTBAD 患者。本研究旨在回顾自胸主动脉内支架植入术问世以来,我院开放性和血管内 CTBAD 修复的当代结果。
回顾性分析 2005 年 6 月至 2013 年 12 月期间我院所有 CTBAD 指数修复患者的记录。
共有 107 例患者接受了 CTBAD 修复,其中 70%(n=75)接受了基于血管内的治疗[44 例 TEVAR、27 例杂交弓和 4 例杂交胸腹主动脉瘤(TAAA)修复],30%(n=32)接受了开放性手术(9 例开放性降主动脉手术和 23 例开放性 TAAA 手术)。结缔组织疾病(CTD)、既往主动脉手术和 DeBakey 夹层类型与手术选择密切相关。基于血管内治疗的手术的卒中、截瘫和手术死亡率分别为 0%、0%和 4%(n=3)。与开放性修复相比,神经不良事件更高,卒中、截瘫和手术死亡率分别为 16%(n=5)、9%(n=3)和 6%(n=2)。然而,基于血管内治疗的修复和开放性修复的 1 年和 5 年生存率相似,分别为 86%和 65%,88%和 79%。在中位数为 34 个月的随访期间,基于血管内治疗的修复后降主动脉再次干预率为 24%(n=18),而开放性修复后为 0%(P=0.001)。44%(n=8)的降主动脉再次干预是为了治疗支架移植物并发症(5 例内漏、2 例支架移植物塌陷和 1 例支架移植物引起的新入口撕裂),其余是为了治疗同时发生的病变(n=2)或与持续性远端开窗相关的进行性瘤样疾病(n=8)。
CTBAD 的血管内修复与出色的程序和生存结果相关,但代价是需要进一步的再次干预。开放性修复仍然适用于不适合血管内修复的患者,并且与更高的程序发病率相关,但总体生存率相似,再次干预较少。